DDInter117 DDInter856
Argatroban is a direct, selective thrombin inhibitor. The American College of Cardiologists (ACC) recommend using bivalirudin or argatroban in patients who have had, or at risk for, heparin induced thrombocytopenia (HIT) and are undergoing percutaneous coronary intervention. Argatroban is a non-heparin anticoagulant shown to both normalize platelet count in patients with HIT and prevent the formation of thrombi. Parental anticoagulants must be stopped and a baseline activated partial thromboplastin time must be obtained prior to administering argatroban.
Unfractionated heparin (UH) is a heterogenous preparation of anionic, sulfated glycosaminoglycan polymers with weights ranging from 3000 to 30,000 Da. It is a naturally occurring anticoagulant released from mast cells. It binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin (factor IIa) and factor Xa. UH is different from low molecular weight heparin (LMWH) in the following ways: the average molecular weight of LMWH is about 4.5 kDa whereas it is 15 kDa for UH; UH requires continuous infusions; activated partial prothrombin time (aPTT) monitoring is required when using UH; and UH has a higher risk of bleeding and higher risk of osteoporosis in long term use. Unfractionated heparin is more specific than LMWH for thrombin. Furthermore, the effects of UH can typically be reversed by using protamine sulfate.
Argatroban {u} (Compound) binds {v} (Gene) CYP3A4
Argatroban {u} (Compound) is included by {v} (Pharmacologic Class) Thrombin Inhibitors
Argatroban {u} (Compound) causes {v} (Side Effect) Haemorrhage
Argatroban {u} may cause a minor interaction that can limit clinical effects when taken with {v} Clove
Argatroban {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Choline salicylate
Argatroban {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alemtuzumab
Argatroban {u} may lead to a major life threatening interaction when taken with {v} Streptokinase
Argatroban {u} may lead to a major life threatening interaction when taken with {v} Danaparoid
Argatroban (Compound) binds CYP3A4 (Gene)
Argatroban (Compound) is included by Thrombin Inhibitors (Pharmacologic Class)
Argatroban (Compound) causes Haemorrhage (Side Effect)
Argatroban may cause a minor interaction that can limit clinical effects when taken with Clove
Argatroban may cause a moderate interaction that could exacerbate diseases when taken with Choline salicylate
Argatroban may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab
Argatroban may lead to a major life threatening interaction when taken with Streptokinase
Argatroban may lead to a major life threatening interaction when taken with Danaparoid